Scilex: Jan ZTlido gross sales $8.1-8.5M (+55-63% YoY); net $3.0-3.6M (+43-71%)

Scilex Holding Co

2022-FY EPS reported -$0.17 revenue$38,034,000

ZTlido gross sales for January 2023 estimated $8.1M-$8.5M, up 55%-63% from $5.2M in January 2022.
Net sales for January 2023 estimated $3.0M-$3.6M, up 43%-71% from $2.1M in the prior year.
Company notes January is historically a low sales month for ZTlido due to managed care deductibles.
Preliminary financial results are unaudited, subject to change, and have not been reviewed by the independent auditor.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scilex Holding Co reported the one month ended January 31, 2023 results: revenue $3.0 million to $3.6 million.

Period: the one month ended January 31, 2023
Revenue: $3.0 million to $3.6 million
Result: preliminary results

Exact text from the filing

The Company estimates that: ZTlido gross sales for January 2023 were in the range of $8.1 million to $8.5 million, compared to $5.2 million in January 2022, representing growth in the range of 55% to 63%; net sales for January 2023 were in the range of $3.0 million to $3.6 million, compared to net sales of $2.1 million in January 2022, representing growth in the range of 43% to 71%.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Scilex Holding Co filing history →

Source: SEC EDGAR

accession 0001193125-23-022210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.